MHRA · Drug safety update ·
Small GBS risk after Abrysvo or Arexvy RSV vaccination
The MHRA says Abrysvo and Arexvy RSV vaccines can very rarely be followed by Guillain-Barré syndrome in older adults.
The Medicines and Healthcare products Regulatory Agency (MHRA) reports a small increase in the risk of Guillain-Barré syndrome after vaccination with Abrysvo (Pfizer RSV vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older.
Guillain-Barré syndrome is a serious nerve condition that often starts in your arms and legs. The MHRA says to be alert for symptoms such as tingling, numbness, pins and needles, muscle weakness, or breathing problems.
RSV (respiratory syncytial virus) is an infection of the airways and lungs that can make older adults seriously ill. The MHRA says urgent hospital treatment is needed if Guillain-Barré syndrome signs appear, and effects may sometimes last long.
The MHRA advises recipients to report suspected side effects after the RSV vaccine on the Yellow Card website. This helps regulators spot and respond to safety signals.
What to do
- Seek immediate medical attention if you notice signs of Guillain-Barré syndrome.
- Report suspected side effects associated with the RSV vaccine on a Yellow Card.